LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mannose-Binding Lectin Associated with IgG Subclass Deficiency

By LabMedica International staff writers
Posted on 11 Jun 2019
Print article
Image: A typical human serum mannose-binding lectin enzyme-linked immunoassay kit (Photo courtesy of Hycult Biotech).
Image: A typical human serum mannose-binding lectin enzyme-linked immunoassay kit (Photo courtesy of Hycult Biotech).
Mannose-binding lectin (MBL; mannan-binding protein or lectin) is involved in innate immune defense, is produced largely by hepatocytes and is encoded by MBL2 (chromosome 10q21.1). MBL promotes killing of microorganisms by complement activation via the lectin pathway and by opsonization.

Immunoglobulin G (IgG), synthesized by plasma cells, is the predominant of five classes of Igs in humans. IgG subclass deficiency (IgGSD) in adults is characterized by: levels of IgG1–3 subclasses more than two standard deviations (SD) below the population mean; frequent or severe respiratory tract infection; suboptimal IgG responses to pneumococcal polysaccharides; and increased prevalence of autoimmune conditions.

Scientists associated with the University of Alabama at Birmingham (Birmingham, AL, USA) studied consecutive unrelated self-identified non-Hispanic white adults (ages ≥18 years) in a single outpatient referral practice who reported having frequent or severe upper or lower respiratory tract infection, were diagnosed to have IgGSD before October 2, 2018, and in whom serum MBL levels were measured. Frequent infection was defined as four or more episodes per year that required antibiotic therapy. Severe infection was defined as any infection that required in-hospital treatment.

Upper respiratory tract infection was defined as reports of sinusitis, otitis media, mastoiditis, pharyngitis, and tonsillitis. Lower respiratory tract infection was defined as reports of bronchitis, pneumonia, and bronchiectasis. Serum Ig levels were measured using standard methods before IgG replacement therapy was initiated, and serum MBL levels were measured using an enzyme-linked immunosorbent assay and specific levels of MBL ≤50 ng/mL were not reported.

The team reported on 219 patients (mean age 51 ± 13 years; 82.5% women). Thirty-six patients (16.4%) had MBL ≤50 ng/mL. Two MBL measurements were available in 14 patients. The median interval between the first and second measurements was 125 days (range 18–1031). Mean MBL levels of patients aged ≤52 y versus > 52 y at diagnosis did not differ significantly. Mean/median MBL levels of men were greater than those of women, but the difference was not significant. Thirty-six of 219 patients (16.4%) had MBL ≤50 ng/mL. Characteristics of patients with and without MBL ≤50 ng/mL did not differ significantly in univariate comparisons. Proportions of IgG subclass immunophenotypes in patients with and without MBL ≤50 ng/mL did not differ significantly.

The authors concluded that the proportion of the present IgGSD patients with serum MBL ≤50 ng/mL is similar to that of healthy European adults. MBL ≤50 ng/mL was not significantly associated with independent variables they studied. The study was published on May 22, 2019, in the journal BMC Immunology.

Related Links:
University of Alabama at Birmingham

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.